AI dog cancer vaccine: ChatGPT story now a startup

No, not directly. Artificial intelligence helped an entrepreneur design a vaccine, not cure the cancer itself. Paul Conyngham used ChatGPT and other tools to create a personalized vaccine for his sick dog.

The tech fairy tale everyone loved, about an AI-created dog cancer vaccine, has a new chapter. Paul Conyngham, an Australian entrepreneur, used ChatGPT to design a personalized mRNA vaccine for his dog's cancer. It's a story that went viral, striking emotional chords.

It's not like ChatGPT put on a lab coat, mind you. The AI acted as an advanced search engine, an assistant for analyzing data and formulating hypotheses. Conyngham's dog, a golden retriever named Gamgee, reportedly recovered thanks to this approach, but the evidence is anecdotal.

Gamgee is the startup launched by Paul Conyngham to offer personalized mRNA cancer vaccines, initially for dogs. The goal is to turn a personal experiment into a commercial service.

After performing a "miracle" on his four-legged friend (or so he claims), Paul thought: why not make a business out of it? The startup Gamgee, founded by Paul Conyngham, aims to offer personalized mRNA cancer vaccines for dogs. It wants to make this technology accessible.

Conyngham's ambitions don't stop at our furry friends. The plan is to expand, one day, to the human sector too. For now, however, he's focusing on the veterinary market. It's a bold step, mixing science, technology, and a good dose of marketing.

It's too early to tell. mRNA vaccine technology is solid and recognized, but the AI's role here is in design, not discovery or clinical validation. Many scientists remain skeptical without concrete evidence.

Let's be honest, a "success" on a single dog is a heartwarming story, not a published scientific paper. No published clinical trials validate the effectiveness of AI-designed dog vaccines. The scientific community requires rigorous, independent testing to confirm these claims.

So, while the idea is fascinating and opens up interesting prospects, we need to keep our feet on the ground. AI can accelerate research, but clinical validation remains a long and fundamental process. There's no shortcut to science, even with the brightest AI.